What is Chardan Capital’s Forecast for SLDB FY2024 Earnings?

Solid Biosciences Inc. (NASDAQ:SLDB) – Equities research analysts at Chardan Capital decreased their FY2024 EPS estimates for shares of Solid Biosciences in a research note issued on Monday, November 11th. Chardan Capital analyst Y. Livshits now expects that the company will earn ($2.91) per share for the year, down from their previous estimate of ($2.72). Chardan Capital currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.78) per share. Chardan Capital also issued estimates for Solid Biosciences’ FY2025 earnings at ($2.03) EPS.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.12).

SLDB has been the topic of a number of other research reports. Barclays decreased their price objective on shares of Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research note on Thursday, November 7th. William Blair upgraded shares of Solid Biosciences to a “strong-buy” rating in a research report on Friday, August 30th. Finally, JPMorgan Chase & Co. decreased their price objective on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Tuesday. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Solid Biosciences has an average rating of “Buy” and a consensus target price of $15.14.

Solid Biosciences Stock Performance

Shares of SLDB stock opened at $4.85 on Thursday. Solid Biosciences has a 52 week low of $2.21 and a 52 week high of $15.05. The stock has a market capitalization of $193.81 million, a PE ratio of -1.60 and a beta of 1.92. The stock’s fifty day moving average is $6.54 and its 200-day moving average is $7.64.

Hedge Funds Weigh In On Solid Biosciences

Several institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP increased its holdings in Solid Biosciences by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 70,827 shares of the company’s stock worth $402,000 after purchasing an additional 5,287 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of Solid Biosciences by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,699 shares of the company’s stock worth $95,000 after buying an additional 7,719 shares during the period. American Century Companies Inc. grew its holdings in shares of Solid Biosciences by 39.9% during the second quarter. American Century Companies Inc. now owns 34,557 shares of the company’s stock worth $196,000 after buying an additional 9,853 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Solid Biosciences in the 3rd quarter valued at approximately $71,000. Finally, Point72 DIFC Ltd acquired a new stake in Solid Biosciences in the 2nd quarter valued at approximately $58,000. Institutional investors own 81.46% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.